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Major improvements in immunosuppressive treatment,
surgical techniques, and treatment of post-transplant
complications have contributed considerably to improved
outcome in renal transplantation over the past decades.
Yet, these accomplishments have not led to similar
improvements in transplant outcome when the results of
living and deceased donors are compared. The enormous
demand for donor kidneys has allowed for the increase in
acceptance of suboptimal donors. The use of brain dead
patients as organ donors has had a tremendous positive
influence on the number of renal transplants. Unfortunately,
the physiologically abnormal state of brain death has a
negative effect on transplant outcome. The fact that
transplanted kidneys derived from brain dead donors have a
decreased viability indicates that potential grafts are already
damaged before retrieval and preservation. In this review, we
present an overview of the current knowledge of
(patho)-physiological effects of brain death and its relevance
for renal transplant outcome. In addition, several options for
therapeutic intervention during brain death in the donor
with the goal to improve organ viability and transplant
outcome are discussed.
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INFERIOR SURVIVAL OF DECEASED DONOR KIDNEYS AFTER
TRANSPLANTATION
Transplant outcome achieved with kidneys from living
donors is far superior when compared to grafts obtained
from deceased donors (Table 1).1,2 The persistent donor
organ shortage has caused longer waiting lists and an
increasing percentage of patients that die while waiting. As
a consequence, a gradual shift toward accepting suboptimal
donors has taken place. The use of older and more marginal
donors is now routine, and the number of non-heart beating
donors has increased significantly over the past years.1,3
Twenty years ago, the typical donor was under the age of 30
years, fairly healthy and died of traumatic cerebral injury.
Today, the average donor is over 50 years old and the main
cause of death is intracranial hemorrhage. The improvements
that were made in treatment regimen of the recipient, organ
preservation, reduction of cold ischemia time, and better
allocation of donor organs have been masked by the use of
lower-quality donors. In the past, much effort was directed
toward post-transplantation immunosuppression and pre-
servation of organs during transport. Now, risk factors and
conditions before organ recovery in the donor need to be
recognized for their impact on donor organ viability. The
detrimental effects of brain death on renal transplant
outcome4,5 have been convincingly shown in the experi-
mental setting. In clinical studies, though, it is difficult to
reveal that brain death itself has an independent influence on
transplant outcome, since living and deceased donors differ
on more aspects than just the death of the brain. However,
when survival rates are stratified for age, grafts from deceased
donors have worse survival within each age-group – even in
the relatively young group of 25–36-year-old donors.2
In 2005, 16 481 renal transplantations were performed in
the United States. Of those, 9913 kidneys originated from
deceased donors and 6568 were recovered from living
donors.1 Yet, at the end of 2004, 57 910 patients were on
the waiting list to receive a renal transplant. For a patient
enlisted in 2000, the median time to transplant was more
than 3 years. Unfortunately, not every patient survived long
enough to receive a transplant, which resulted in approxi-
mately 3000 deaths on the waiting list in that same year. The
increased demand for donor kidneys has provoked a large
shift toward living kidney donation in the United States.1 In
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fact, the number of living kidney donors in the United States
surpassed the number of deceased donors in 2000.1,6 Still, the
total number of kidneys obtained from living donors is lower
since in living donation only one kidney can be donated,
while in deceased donors both kidneys are recovered. In
many European countries, the use of living donors has
increased as well over the past decade, albeit more modestly.3
In their 1995 landmark paper, Terasaki et al.2 showed that
graft survival for living unrelated donation is superior
compared to deceased donation, even though the average
human leukocyte antigen-haplotype matching is worse in
living unrelated donation. Long-term outcome after living
unrelated donation is similar to that of parental or offspring
donors.7 This indicates that poor survival of grafts from
deceased donors cannot be solely attributed to differences in
immunogenicity. Graft performance is affected by many
other factors. Donor variables such as age, gender, race,
terminal serum creatinine, history of hypertension, and cause
of death all affect transplantation outcome.8–10 Deceased
donors tend to be older than living donors;1 however, within
each age category, survival rates of living donor grafts are
significantly higher than those of deceased donor grafts.2
Preservation and cold ischemia time influence transplant
outcome, and for logistical reasons, cold ischemia time
is longer on average in deceased donor transplantation.
For renal transplantation, cold ischemia time of more
than 24 h is associated with worse outcome after renal
transplantation.2,11,12
Despite the fact that grafts obtained from deceased donors
have inferior outcome, these transplants have prevented
death for many people on dialysis. Deceased donor kidney
recipients have a 68% reduced risk of mortality compared to
similar patients who stay on the waiting list receiving dialysis
treatment.13 The shortage of donor organs culminated in the
use of extended criteria donation (ECD). ECD includes brain
dead donors who are older than 60 years, or are aged over 50
years in combination with at least two of the following risk
factors: a history of hypertension and a terminal serum
creatinine 41.5 mg/dl or a cerebrovascular cause of death.
The number of ECD-derived kidneys has seen marginal but
steady increase over the past years,1 even though long-term
allograft survival of ECD-derived kidneys is inferior com-
pared to non-ECD kidneys (Figure 1).1,14 Initial doubt about
the advantages of this type of donor has not been sustained.
Relative mortality risk analysis has shown that the short-term
risk of death in ECD kidney recipients is more than five times
higher when compared to standard therapy with dialysis
while waiting for a non-ECD kidney. At 226 days after
transplantation, however, the risk becomes equal and is lower
thereafter. In addition, the long-term cumulative mortality is
significantly lower in ECD kidney recipients.15 Kidneys
discarded by transplant centers twice or more for reasons
of poor organ quality showed worse initial non-function and
long-term renal performance. Five-year graft and patient
survival, however, were not significantly different from
control kidneys that were immediately accepted.16 Counter-
acting the deleterious effects that brain death has on these
already compromised organs could positively affect trans-
plant outcome and reduce the number of discarded organs,
thereby increasing the number of successfully transplanted
kidneys.
BRAIN DEATH, SYSTEMIC CHANGES, AND CLINICAL COURSE
The beating heart has always been considered the classic sign
of life. After the report by Mollaret and Goulon17 in 1959
which described comatose patients with vital functions
sustained by mechanical ventilation, the definition of death
became a major point of discussion. Owing to improved
techniques, the heart was kept functioning in these patients
while mechanical ventilation oxygenated the blood. Judged
by their appearance, patients did not look deceased; however,
it was clear that normal, self-sustained function would never
be regained. In 1963, before a consensus had been reached on
the implications of this irreversible coma, the first kidney was
recovered from a brain dead, heart-beating donor and
transplanted by the Belgian surgeon Alexandre.18 In an effort
to overcome problems that led to controversy in obtaining
organs from deceased donors, but also to decrease the burden
on the relatives of brain dead patients on life support, an ad
hoc committee of the Harvard Medical School proposed to
add irreversible coma to the death criterion in 1968.19 This
report generated considerable medico-legal discussion and
resulted in most countries adopting a concept of death that
originates from this proposition. The definition of brain
death that the committee proposed concerned the following
mandatory criteria: (1) unawareness of and unresponsiveness
to external stimuli, (2) no spontaneous movements or
Table 1 | 1- and 5-year graft survival for living and deceased
donors following renal or liver transplantation.
1-year survival
Organ
transplanted
Kidney
Living donor 94.3% 94.6% 78.6%
88.7% 89.0% 65.7%
79.3% 80.1% 78.1%
80.6% 81.4% 64.1%
79.2%
66.2%
71.2%
65.4%
Deceased donor
Living donor
Deceased donor
Liver
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Figure 1 | Graft survival over a period of 5 years for living-,
non-ECD- and ECD-derived renal grafts. Source: UNOS/OPTN
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breathing, (3) absent reflexes, and (4) a flat electroencephalo-
gram. Caution is required for conditions that can elicit
similar symptoms, such as hypothermia, hypotension, or
intoxication, and therefore these have to be ruled out.
Brain death as such is the terminal phase of a sequence of
events frequently commencing with cerebral trauma or
cerebrovascular hemorrhage. When the patient is declared
brain dead, this chain of events has already affected the
organs. Systemic and hormonal changes arise immediately
when intracranial pressure increases. Hence, brain death is
not the stationary condition as perceived from the outside,
but a dynamic and rather unphysiological course of events
that influences a number of (patho-)physiological processes
in the human body (Figure 2).
Hemodynamic changes
Following cerebral trauma or injury, the primary rise in
intracranial pressure causes additional damage to the
cerebrum, which triggers parasympathetic activity and results
in a decreased systemic blood pressure. The continued rise in
intracranial pressure leads to herniation of the brain stem
through the foramen magnum, which is accompanied by
arterial compression and ultimately occlusion with progres-
sive ischemic damage. When the pontine part of the brain
stem becomes ischemic, sympathetic stimulation, together
with the persisting parasympathetic activity, will cause the
Cushing reflex, which was already described in 1902 by the
American neurosurgeon Harvey Cushing.20 The Cushing
reflex consists of multiple disturbances in the physiology of
cerebrally injured patients, including bradycardia, hyperten-
sion and an irregular breathing pattern. Ultimately, when the
entire brain stem has become ischemic, the vagal cardio-
motor nucleus is affected and solitary sympathetic stimula-
tion will occur. As a result, massive catecholamine release,
systemically as well as from myocardial sympathetic nerve
endings, cause an increase in heart rate and leads to
vasoconstriction with increased vascular resistance and blood
pressure.21–23 This process is referred to as the sympathetic or
catecholamine storm, and is considered to be an attempt of
the body to raise arterial blood pressure above the elevated
intracranial pressure as an ultimate effort to restore perfusion
of the cerebrum.
The rise in serum epinephrine levels has been reported to
be as high as 100–1000-fold higher compared to normal
values in animal models of brain death.23–26 The magnitude
of catecholamine release is related to the severity of brain
damage. The faster the rise in intracranial pressure, the
higher the peak in catecholamine levels.23 Also, serum
norepinephrine and dopamine concentrations are vastly
increased after onset of brain death. The values of
Brain death
Cerebral injury and edema
Brain stem herniation
Hormonal Changes
↓ADH
↓ACTH
↓T3/T4/TSH
Volume depletion
Diabetes insipidus
Renal hypoperfusion
↑ROS production
Ischemia?
Endothelial activation
Influx of leukocytes
(Peri)glomerulitis
↑Coagulation
Induction of cytoprotection
↑HO-1/HSP70/MnSOD2
Reduced organ viability
↑Allo-response
↑Delayed graft function
↑Chronic allograft nephropathy
Hemodynamic instability
Catecholamine storm
Hypovolemia
Immunological activation
Cytokine storm
Systemic inflammatory response
Complement activation
Figure 2 | Proposed model for the (patho)-physiological changes associated with brain death.
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catecholamine release in animal experiments appear to be
similar to those described in the clinical situation.27 In
addition, a parallel cardiac response to brain injury is seen, as
demonstrated by even higher levels of myocardial catecho-
lamines compared to the serum28 leading to injury of
myocytes.21,29 The catecholamine-induced increase in vascu-
lar resistance can be severe, reaching four times higher levels
than basal values in the rat kidney.26 This causes renal blood
flow to decrease by a factor of 2.4 and supports the
hypothesis that the rigorous decline in organ perfusion leads
to ischemic damage of potential grafts.
Over time, sympathetic pathways are deactivated due to
ischemia of the spinal cord. This leads to a gradual decrease
of the hyperdynamic state with a subsequent decline in blood
pressure, heart rate, and cardiac output to normal or
subnormal values. Ultimately, a state of hypoperfusion is
reached, which is harmful to the potential donor kidneys.
Prolonged brain death results in high rates of tubular
necrosis.30 Many brain dead patients need hemodynamic
support during this phase, and receive vasopressors and/or
anti-diuretic hormone.
Hormonal changes
In addition to the catecholamines, other hormonal altera-
tions take place. There is evidence that some residual cerebral
blood flow and hypothalamic function can persist after brain
death.31–33 In most brain dead patients, however, a gradual
decrease in the release of adrenocorticotropic hormone and
anti-diuretic hormone is seen,24,25,34 which is associated with
cardiovascular failure that eventually causes the requirement
of hemodynamic support. The failure to keep anti-diuretic
hormone levels in the range needed for a normal osmolar-
ity24,25,31 has been suggested as the cause of diabetes insipidus
in up to 78% of patients.34,35 A more recent explanation is
the downregulation of aquaporin-2 channels,36 which could
affect water re-uptake in the renal collecting ducts. Free-
circulating triiodothyronine (T3) gradually decreases after
brain death,34,35,37–40 but not every study has found
comparable results concerning the serum concentrations of
T3 and T3-related hormones, such as T4 and TSH.32,39–41
Any acute stress will enhance the condition known as
‘diabetes of injury,’ consisting mainly of hyperglycemia
caused by increased gluconeogenesis and insulin resistance.
Intensive insulin therapy is now applied in many intensive
care units, and as a result mortality in intensive care units has
been greatly reduced when strict glycemic control is
achieved.42,43 A lower incidence of newly acquired renal
injury, earlier weaning from mechanical ventilation, and a
faster discharge from the intensive care unit and from the
hospital were observed.43 The rise in serum creatinine was
attenuated by the maintenance of normoglycemia. Also,
insulin therapy reduces the inflammatory response: ICAM-1
and C-reactive protein are both decreased in the serum of
intensive care unit patients receiving intensive insulin
treatment.44,45 Thus, the use of intensive insulin therapy in
brain dead patients could attenuate renal damage, reduce
inflammation, and enhance donor organ viability resulting in
a better transplantation outcome.
EXPERIMENTAL BRAIN DEATH MODELS
To obtain a better insight in the (patho-)physiological
processes that occur during brain death, standardized models
have been developed to investigate the discrepancies in
outcome between deceased and living donor transplantation.
In these models, the detrimental effects of brain death can be
studied and possible interventions evaluated.46–49 Various
research groups have studied brain death in the rat model.
Epidural hematoma is simulated using an inflatable catheter
inserted through a trepanation in the skull. Inflation of the
catheter causes cerebral damage followed by edema, a rise in
intracranial pressure and eventually herniation of the brain
stem. The models vary in details such as the speed of balloon
catheter inflation and the use of hemodynamic support.
Brain death can be confirmed – as in the human situation –
by the absence of the apnea reflex, cornea reflex, and
observation of the typical course of blood pressure changes.
The effects of brain death induction in the current animal
models of brain death closely mirror observations from the
clinical situation.
In recent years, the use of animal models with brain death
has made it clear that organ quality is significantly affected
and frequently diminished in brain dead animals. In contrast
to the clinical circumstances, in the animal model, hetero-
geneity is reduced and the pathophysiology of cerebral injury
leading to brain death in donors can be studied in far greater
detail.
PATHOPHYSIOLOGICAL EFFECTS OF BRAIN DEATH ON RENAL
FUNCTION AND STRUCTURES
Before 1997, the concept of brain death did not exist in
Japan. Patients who would be considered brain dead and
eligible for organ donation in the United States or Europe
were kept in a coma until cardiac arrest. This presented
Nagareda et al.30 with the unique opportunity to investigate
the time course of the effects of brain death on the kidney up
to 48 days. Their study revealed that the mean urinary
sodium output increased during the first 14 days, mean urine
osmolarity was above normal on the first day but decreased
gradually, and urine volume during the first 14 days was high
as a consequence of the cerebral injury-related diabetes
insipidus. On histological examination, degenerative changes
of renal structures were found, including vacuolization,
atrophy, and necrosis of renal proximal and distal tubules.
Advancing glomerulitis and progressing periglomerulitis
expressed inflammatory changes. Periglomerular fibrosis
and proliferation of the arterial intima and glomerular
endothelium reflected the structural changes in the kidney.
In experimental conditions in rats, renal function is
already negatively affected during 4 h of brain death followed
by inferior results after reperfusion in an isolated perfused
kidney set up. During isolated perfused kidney, urine volume,
and glomerular filtration rate were significantly higher than
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controls.50 Interestingly, potassium excretion was increased in
these kidneys, possibly explained by the depletion of ATP in
these kidneys, which can trigger the opening of ATP-sensitive
potassium channels (KATP channels). An impaired sodium/
potassium homeostasis was observed after brain death in a
renal slice model as well.51 Organs can also become more
prone to ischemia/reperfusion injury: livers derived from
brain dead rats are more susceptible to cold storage-induced
injury. This was demonstrated by a decreased survival after
20 h of cold storage when compared to living donor livers
stored equally long.52
Renal tubular damage as a consequence of brain death
can be observed in urine as well. Brush-border enzymes, such
as alkaline phosphatase and alanine amino peptidase, as
well as the lysosomal enzyme N-acetyl-b-D-glucosamini-
dase,50 are released into the urine. Kidney injury molecule-1,
is a recently discovered brush-border enzyme which is
considered a marker of tubular damage, for example, in
ischemia/reperfusion injury.53 As a result of brain death, we
found that kidney injury molecule-1 is massively upregu-
lated. Interestingly enough, it can be detected on the luminal
side of the renal cortical tubule, but is also shed into the
urine,54 which may simplify viability assessment of potential
donor organs.
Immunological activation
In ischemia/reperfusion injury, a clear-cut correlation
was found between endothelial injury and acute rejection.
This association between the innate immune response and
subsequent alloreactivity could be explained by Matzinger’s
danger hypothesis.55 It is of importance that an increased
immunogenicity is also observed in the brain dead donor
organ as well. Endothelial activation is present with the
upregulation of adhesion molecules (E-selectin, P-selectin,
intracellular adhesion molecule-1, and vascular cellular
adhesion molecule-1) that promote the rolling, adhesion,
diapedesis, and subsequent leukocyte migration into the
interstitium of the kidney.46,56–59 Multiple cytokines and
chemokines do play a role in the immunological response to
cerebral injury. Upregulation of interleukin (IL)-1, IL-2, IL-6,
tumor necrosis factor-a, transforming growth factor-b,
interferon-g, vascular endothelial growth factor, macrophage
inflammatory protien-1a, macrophage inflammatory pro-
tien-1b, membrane cofactor protein-1, and osteopontin have
been reported.36,56,58,60 The expression of the major histo-
compatibility complex class II is increased as well.56
Amplification of cytokines, chemokines, and adhesion
molecules causes a chemotactic gradient that promotes the
influx of leukocytes to the kidney. T cells, macrophages, and
polymorphonuclear leukocytes are all found in higher
quantities in donor kidneys during brain death.46,56,57,61
After reperfusion, a large difference in neutrophil infiltra-
tion and P-selectin expression can be observed between living
and deceased donor grafts. Koo et al.62 showed that 53% of
deceased donor renal allografts had increased neutrophil
infiltration, against 0% of living related grafts. P-selectin
expression was increased in 44% of deceased donor grafts,
and 9% of living related grafts.
In a syngeneic animal model of renal transplantation,
short-term inflammatory changes to the kidneys were
investigated by Kusaka et al.58 The extent of leukocyte
infiltration reaches its peak at 24 h after transplantation in
this syngeneic transplant model and corresponds with the
levels of E- and P-selectin. After this period, the extent of
immunological activation gradually decreases, but histologi-
cal changes to the kidney can still be observed. Allotransplant
experiments have shown that after experimental brain death,
recipients of brain dead donor kidneys suffered from a greatly
increased acute rejection rate.4 Similar effects have been
observed in other organs, such as lung63 and heart.64 When
kidney allografts are treated with cyclosporine to prevent
acute rejection, long-term renal function is adversely affected
by brain death compared to syngeneic transplants. Thus, the
state of brain death can also enhance the development of
chronic renal transplant dysfunction.5
Protection and repair
Interestingly, not only detrimental or degenerative
changes take place during brain death. Protective or
recuperative mechanisms are induced as well. This is reflected
by increased expression of the cytoprotective genes
heme oxygenase-1 (HO-1), heat-shock protein 70, and
manganese superoxide dismutase.36,61,65 Kunzendorf et al.66
showed that a prolonged duration of brain death positively
influences long-term graft survival. The mechanism behind
this observation could well be the delayed induction of
protection or initiation of repair. In another study, increased
HO-1 expression at organ recovery was correlated
with outcome after renal transplantation in the living
donor setting.61 Expression of HO-1 was not related to
graft survival in deceased donor kidneys. Donor HO-1 gene
polymorphisms have been associated with transplantation
outcome.67 Surprisingly, in a liver transplant study,
livers with an initial low HO-1 expression before transplanta-
tion, but a high HO-1 expression after reperfusion,
had superior outcome when compared to livers with high
HO-1 expression at organ recovery.68 These observations
indicate that the ability to induce HO-1 is important, and not
a high expression of HO-1 per se. Two different mechanisms
should be considered here: while the increase in expression of
HO-1 in living donors may initiate protection against the hits
to the kidney during transplantation and thereafter, in
deceased donors, on the other hand, HO-1 may well be a
reflection of the level of stress to the kidney due to brain
death.
EXPERIMENTAL AND CLINICAL INTERVENTIONS
Different concepts and approaches have been considered to
counteract the detrimental effects caused by brain death
(Table 2). Some research groups focus on the induction of
protective proteins, while others aim at reducing the immune
response.
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In a case–control study performed by Schnuelle et al.,69
treatment of the donor with the vasopressors dopamine or
noradrenalin was identified as an independent beneficial
factor in renal transplant outcome. They confirmed these
results in a study using the Eurotransplant database,70 and
also in a recent study, where donor dopamine was found to
be associated with a more rapid decrease in serum creatinine
and better long-term survival.71 Experimentally, dopamine
treatment has shown beneficial effects in a model of brain
death induced renal damage. Dopamine treatment resulted in
HO-1 induction as well as an inhibition of P-selectin
expression and decreased mononuclear infiltration.48 In
other experiments, the effects of ischemia/reperfusion and
cold preservation were attenuated by low-dose dopamine
treatment.72,73 In vitro, decreased production of chemokines,
chemokine (C-X-C motif) ligand 1 (CXCL-1), epithelial
neutrophil activating peptide-78 (ENA78), and IL-8 in
proximal tubular epithelial cells, has been observed after
dopamine treatment.74 In endothelial cells, production of
CXCL-1 and ENA78 was reduced, but IL-8 increased. In
addition, dopamine pretreatment delayed expression of
intracellular adhesion molecule-1, and vascular cellular
adhesion molecule-1 after tumor necrosis factor-a stimula-
tion in these cells. These immunological effects seen in
experimental conditions could be part of the explanation for
the improved renal transplantation outcome after catecho-
lamine treatment of the brain dead donor.
Selective upregulation of HO-1 has proven to be beneficial
in different models of stress or damage, including ischemia/
reperfusion75 and experimental renal transplantation.76
Owing to its antioxidative, antiapoptotic, and immune
regulatory effects, HO-1 has become an extensively investi-
gated protein in the search for protection against insults
during and before the transplant process. Experimental
transplantation after upregulation of HO-1 by cobalt
protoporphyrin treatment in the brain dead donor resulted
in improved renal allograft survival.77 Also, a reduction was
seen in the infiltration of ED1þ monocytes/macrophages,
CD4þ T cells and CD8þ T cells in the cobalt protoporphyr-
in-treated group. The application of novel and existing
approaches in the field of HO-1 induction can therefore be
regarded as a promising possibility to improve clinical renal
transplant outcome.
Inhibition of the immunological activation due to brain
death is one of the strategies to improve transplant outcome
in experimental models. Glucocorticosteroid treatment of
brain dead rats improved graft survival after transplantation
to a level comparable with living donor transplants.78
Steroids suppress cellular infiltration and expression of
cytokines and the intensity of morphological changes are
noticeably different in the recipients of a graft from an
untreated brain dead donor. The only prospectively designed
human study known to us has reported some promising
results in reducing the expression of proinflammatory
cytokines using steroid therapy.79 Long-term results after
kidney transplantation, however, have yet to be reported.
Treatment of the donor with the recombinant soluble
P-selectin glycoprotein ligand, an inhibitor of P- and E- and
L-selectin, has also been shown as advantageous in experi-
mental models.78,80 Three days after transplantation, un-
treated brain dead donor kidneys showed severe tubular
necrosis and mononuclear infiltration, whereas recipients
where the donor was treated with recombinant soluble
P-selectin glycoprotein ligand showed similar serum
Table 2 | Overview of studies that investigated the effects of specific interventions on brain death related damage
Study
Human studies
Kuecuek (2005)79 Steroids Reduced expression of proinflammatory cytokines
Improved graft survival, less acute rejection
Improved graft survival, less acute rejection
Improved graft survival, improved short-term renal function
Improved graft survival
Reduced expression of proinflammatory factors
Improved graft survival, reduced chronic rejection
Improved graft survival, reduced leukocyte infiltration
Improved graft survival, reduced acute rejection
Reduced monocyte infiltration, reduced expression
proinflammatory factors
Improved graft survival, reduced acute rejection
Dopamine
Norepinephine
Catecholamines§
Dospamine
Dospamine
CEPO
rPSGL-lg
rPSGL-lg
Steroids
CoPP (HO-1induction)
Schnuelle (1999)69
Schnuelle (2001)70
Schnuelle (2004)71
Animal studies
Coleman (2006)83
Gasser (2002)80
Kotsch (2006)77
Pratschke (2001)78
Schaub (2004)48
Treatment Main renal outcome
CEPO, carbamylated erythropoietin; rPSGL-Ig, recombinant P-selectin glycoprotein ligand; CoPP, cobalt protoporphyrin; HO-1, heme oxygenase-1.
yCatecholamine treatment was defined as administration of any of the following adrenergic substances: dopamine, norepinephrine, epinephrine, dobutamine.
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creatinine levels to living donor iso- and allograft recipients.
In addition, recombinant soluble P-selectin glycoprotein
ligand treatment was able to affect chronic transplant
dysfunction in animals that received brain dead donor
kidneys, reducing long-term graft injury to a level seen in the
living donor situation.
Carbamylated recombinant human erythropoietin is an
EPO derivative that does not have hematopoietic effects, but
has tissue-protective capacities in different models of neural
damage such as stroke.81 Recently, we found that carbamy-
lated recombinant human erythropoietin can reduce the renal
inflammatory response and attenuate the increase in serum
creatinine levels due to brain death82,83 Also, an improved
glomerular filtration rate was observed in kidneys derived
from carbamylated recombinant human erythropoietin-trea-
ted brain dead rats compared to untreated controls. The
combination of immunomodulation and tissue protection
could be effective in reducing brain death-related damage.
PERSPECTIVES ON DONOR MANAGEMENT AND
PRETREATMENT
The deleterious effects of brain death on the donor kidney
provoke pathophysiological changes that have a negative
impact on the outcome after transplantation. Ischemia of the
brain results in non-function of the central nervous system,
and is associated with pertinent hemodynamic instability,
hormonal changes, and diminished perfusion. This abnormal
physiological state induces proinflammatory changes in the
potential donor organs that negatively affect function and
cause an increased chance of acute rejection. These
compromising changes in the donor urge us to develop
treatment regimens for application during brain death.
The use of pharmacological interventions to provide
optimal conditions for the donor organ and prevent the
decline of renal function will become an important part of the
entire donation and transplantation process. Reducing hemo-
dynamic instability is crucial to maintain normal perfusion of
organs. The use of catecholamines for this purpose would
benefit renal transplant outcome. Caution is needed, however,
since interventions that can be of benefit to one organ may be
detrimental to another. This was demonstrated by Schnuelle
et al.70 in their analysis of catecholamine use in the donor.
Although renal transplant survival was increased, liver
transplant outcome was not improved and cardiac results
appeared to be adversely influenced by catecholamine
administration in the donor. A randomized prospective
clinical trial is currently underway to assess the effects of
donor pretreatment with dopamine (Table 3).
The application of intensive insulin therapy for strict
glycemic control could be beneficial to prevent damage to the
organs during brain death. It is not clear yet if the effect will
be large enough, however, to have consequences for graft
viability and transplant outcome.
The use of immunomodulators, such as steroids or
recombinant soluble P-selectin glycoprotein ligand, has
shown some promising results in experimental models.
Counteracting inflammatory changes in the deceased donor
kidney improved function and survival after transplantation.
In fact, steroid treatment is effective in modulating the
immune response in human organ donors.79 Since all organs
exhibit inflammatory changes as a result of brain death,
immunomodulating treatment has a high probability to be of
benefit for all transplanted organs.
The induction of protective mechanisms, such as HO-1
upregulation, is an important development in donor
pretreatment. Initiation of protective pathways can diminish
brain death-related damage and ischemia/reperfusion injury.
The products created during heme degradation by HO-1 are
involved in cytoprotective processes. In addition, immuno-
modulating effects of HO-1 could be of use in the
improvement of deceased donor transplantation. Another
option is the addition of gaseous substances to the breathing
air of brain dead donors. Carbon monoxide has demons-
trated a beneficial effect in modulating ischemia/reperfusion
injury,84 and low-dose inhalation of carbon monoxide after
experimental renal transplantation prevents the development
of chronic allograft nephropathy.85
To date, many challenging opportunities do exist to
counteract the deleterious effects of brain death on the donor
kidney. A better characterization and understanding of the
mechanisms of injury and repair that play a role during
massive cerebral injury and its effect on potential donor
organs will lead to novel treatment options. As a result, the
Table 3 | Interventions that counteract the negative effects of
brain death on the kidney, or could be used for this purpose
in the future
Potential interventions for in the brain dead donor
Catecholamines (Dopamine, Epinephrine, Norepinephrine)
Antidiuretic hormone (ADH)
Immunosuppressants (Glucocorticods, Calcineurin inhibitors)
Monoclonal antibodies against cytokines (TNF-α, IFN-γ, IL-2, IL-6
Inhibitors of chemokines (MCP-1, MIP-1α, MIP-1β)
Carbamylated recombinant human Erythropoietin (CEPO)
Recombinant P-Selection Glycoprotein Ligand–lg (rPSGL-lg)
HO-1 induction (Cobalt Protoporphyrin (CoPP)),
HSP induction (Pyrrolidine Dithicarbamate (PDTC),
Geranylgeranylacetone (GGA))
Selective inhibitors of kinases (JNK, p38, ERK, RhoA)
Carbon Monoxide (CO)
Nitrous Oxide (NO)
Intensive insulin therapy
Hemodynamic
Anti-inflammatory
Induction of cytoprotection
Signal transduction
Gaseous substances
Hormonal
ERK, extracellular signal-regulated kinase; IL, interleukin, IFN-g, interferon-g; JNK, Jun
N-terminal kinase; MCP-1, membrane cofactor protein-1; MIP-1a, macrophage
inflammatory protein-1a, MIP-1b, macrophage inflammatory protein-1b; TNF-a,
tumor necrosis factor-a.
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outcome after deceased donor organ transplantation may
improve, and approach that of living donors.
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